<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03666884</url>
  </required_header>
  <id_info>
    <org_study_id>UsakSH</org_study_id>
    <nct_id>NCT03666884</nct_id>
  </id_info>
  <brief_title>The Comparison of 50% AS Versus PFAT+ 0.05 % COE in Severe Dry Eye Syndrome</brief_title>
  <official_title>The Comparison of 50 % Concentration Autologous Serum Eye Drops Versus Preservative Free Artificial Eye Drop Plus 0.05 % Cyclosporin Ophthalmic Emulsion in the Treatment of Severe Dry Eye Syndrome: A Randomized Comparative Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seref istek</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Usak State Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Usak State Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present study aimed to evaluate and compare the efficacy of a 1 month clinical trial of
      50% AS for the treatment of severe dry eye syndrom (DES) based on Schirmer's Test, tear
      break-up time (TBUT), fluorescein staining, and ocular surface disease index (OSDI) scores,
      as compared to conventional preservative-free artificial tears (PFAT) plus 0.05% COE
      treatment in patients with severe DES
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an retrospective comparative study. The designation of the patient whether to use AS
      8*1 or conventional PFAT 8*1 plus COE 2*1 was determined randomly. Student's paired samples
      t-test, independent samples Student's t-test, Wilcoxon signed-rank test and Mann-Whitney U
      test were used to compare data. All patients responded well to both treatments after the
      first 1-month treatment period, based on comparison of before and after treatment OSDI
      scores, Schirmer's test results, TBUT values, and OXFORD scale scores.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 10, 2015</start_date>
  <completion_date type="Actual">October 25, 2016</completion_date>
  <primary_completion_date type="Actual">March 15, 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The comparison of 50 % concentration autologous serum eye drops versus preservative free artificial eye drop plus 0.05 % cyclosporin ophthalmic emulsion in the treatment of severe dry eye syndrom</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
    <masking_description>Participants chose their treatment regime randomly</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>schirmers test 1 result</measure>
    <time_frame>first month results after two treatment regimes for severe dry eye groupes, 5 minutes tear drop wetness of schirmers paper in milimeters</time_frame>
    <description>clinical improvement in schirmer's test 1 result</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ocular surface oxford scale</measure>
    <time_frame>first month results after two treatment regimes for severe dry eye groupes, dry eye symptom scale graded 1 to 4</time_frame>
    <description>clinical improvement in oxford scale</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ocular surface disease index scale (OSDI)</measure>
    <time_frame>first month results after two treatment regimes for severe dry eye groupes, dry eye symptoms graduation prepared with sample questions concluded in 2 digit numbers from 25 to 100,</time_frame>
    <description>clinical improvement in OSDI</description>
  </primary_outcome>
  <primary_outcome>
    <measure>tear break up time</measure>
    <time_frame>first month results after two treatment regimes for severe dry eye groupes, dry eye quantitave assesment of tear break up time in seconds graded from 0 sec to 10 seconds 10 the best 0 the worst</time_frame>
    <description>clinical improvement in tear break up time</description>
  </primary_outcome>
  <primary_outcome>
    <measure>fluorescein staining of eye</measure>
    <time_frame>first month results after two treatment regimes for severe dry eye groupes, graduation of dry eye clinical examination graded from 1 to 4</time_frame>
    <description>clinical improvement in fluorescein staining of eye</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Dry Eye Syndrome</condition>
  <arm_group>
    <arm_group_label>dry eye patients 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>dry eye patients treated for 1 month and patient symptoms after 1 month</description>
  </arm_group>
  <arm_group>
    <arm_group_label>dry eye patients 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>dry eye patients treated for 1 month and patient symptoms after 1 month</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>COE 2*1 (Restasis) + PFAT Refresh Single dose) 8*1</intervention_name>
    <description>clinical improvement in oxford scale, ocular surface disease index, schirmers test, tear break up time, fluorescein staining of eye</description>
    <arm_group_label>dry eye patients 1</arm_group_label>
    <arm_group_label>dry eye patients 2</arm_group_label>
    <other_name>Restasis+Refresh Single Dose</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AS 50% eye drops 8*1</intervention_name>
    <description>clinical improvement in oxford scale, ocular surface disease index, schirmers test, tear break up time, fluorescein staining of eye</description>
    <arm_group_label>dry eye patients 1</arm_group_label>
    <arm_group_label>dry eye patients 2</arm_group_label>
    <other_name>50% autologous serum eye drops 8*1</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  refractory to conventional treatment (those that did not respond well to entire dry
             eye medications containing hydroxypropyl methylellulose, carboxyl methylcellulose,
             polyvinyl alcohol, polyethylene glycol-propylene glycol, sodium hyaluronate, mineral
             oil, dextran, and carbomer artificial tears with or without preservatives)

          -  had low TBUT (&lt; 5 s) (5μL of fluorescein sodium 2% eye drops was used)

          -  low Schirmer's test I score without topical anesthesia ( basic+reflex secretion),
             positive corneal and conjunctival fluorescein staining (≥grade 1 according to the
             OXFORD Scale) (3) and an OSDI score &gt; 40 OSDI was a reliable and valid test for
             quantifying the severity of dry eye symptoms

        Exclusion Criteria:

          -  active ocular infection or any other inflammation not associated with dry eye

          -  a severe associated ocular allergy, eyelid or eyelash abnormality

          -  current contact lens use, history of refractive surgery

          -  associated glaucoma

          -  current use of any type of topical eye drops other than dry eye medications

          -  any known graft-versus host disease

          -  known severe anemia (hemoglobin&lt;11 g/dL-1)

          -  medically uncontrolled significant cerebrovascular and cardiovascular disease

          -  pregnant and lactating patients
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>şeref istek, doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Ophtalmology, Usak State Hospital</affiliation>
  </overall_official>
  <results_reference>
    <citation>Bradley JC, Bradley RH, McCartney DL, Mannis MJ. Serum growth factor analysis in dry eye syndrome. Clin Exp Ophthalmol. 2008 Nov;36(8):717-20. doi: 10.1111/j.1442-9071.2008.01895.x.</citation>
    <PMID>19128374</PMID>
  </results_reference>
  <results_reference>
    <citation>Research in dry eye: report of the Research Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf. 2007 Apr;5(2):179-93. Review.</citation>
    <PMID>17508121</PMID>
  </results_reference>
  <results_reference>
    <citation>Bron AJ, Evans VE, Smith JA. Grading of corneal and conjunctival staining in the context of other dry eye tests. Cornea. 2003 Oct;22(7):640-50. Review.</citation>
    <PMID>14508260</PMID>
  </results_reference>
  <results_reference>
    <citation>Pflugfelder SC, Solomon A, Stern ME. The diagnosis and management of dry eye: a twenty-five-year review. Cornea. 2000 Sep;19(5):644-9. Review.</citation>
    <PMID>11009316</PMID>
  </results_reference>
  <results_reference>
    <citation>Fox RI, Chan R, Michelson JB, Belmont JB, Michelson PE. Beneficial effect of artificial tears made with autologous serum in patients with keratoconjunctivitis sicca. Arthritis Rheum. 1984 Apr;27(4):459-61.</citation>
    <PMID>6712760</PMID>
  </results_reference>
  <results_reference>
    <citation>Tsubota K, Goto E, Fujita H, Ono M, Inoue H, Saito I, Shimmura S. Treatment of dry eye by autologous serum application in Sjögren's syndrome. Br J Ophthalmol. 1999 Apr;83(4):390-5.</citation>
    <PMID>10434857</PMID>
  </results_reference>
  <results_reference>
    <citation>López-García JS, García-Lozano I, Rivas L, Martínez-Garchitorena J. [Use of autologous serum in ophthalmic practice]. Arch Soc Esp Oftalmol. 2007 Jan;82(1):9-20. Review. Spanish.</citation>
    <PMID>17262232</PMID>
  </results_reference>
  <results_reference>
    <citation>Rybickova I, Vesela V, Fales I, Skalicka P, Jirsova K. Apoptosis of conjunctival epithelial cells before and after the application of autologous serum eye drops in severe dry eye disease. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2016 Jun;160(2):271-5. doi: 10.5507/bp.2016.001. Epub 2016 Feb 29.</citation>
    <PMID>26927466</PMID>
  </results_reference>
  <results_reference>
    <citation>Gao J, Schwalb TA, Addeo JV, Ghosn CR, Stern ME. The role of apoptosis in the pathogenesis of canine keratoconjunctivitis sicca: the effect of topical Cyclosporin A therapy. Cornea. 1998 Nov;17(6):654-63.</citation>
    <PMID>9820947</PMID>
  </results_reference>
  <results_reference>
    <citation>Ridder WH 3rd. Ciclosporin use in dry eye disease patients. Expert Opin Pharmacother. 2008 Dec;9(17):3121-8. doi: 10.1517/14656560802500613 .</citation>
    <PMID>19006483</PMID>
  </results_reference>
  <results_reference>
    <citation>Yüksel B, Bozdağ B, Acar M, Topaloğlu E. Evaluation of the effect of topical cyclosporine A with impression cytology in dry eye patients. Eur J Ophthalmol. 2010 Jul-Aug;20(4):675-9.</citation>
    <PMID>20155706</PMID>
  </results_reference>
  <results_reference>
    <citation>Vitali C, Bombardieri S, Jonsson R, Moutsopoulos HM, Alexander EL, Carsons SE, Daniels TE, Fox PC, Fox RI, Kassan SS, Pillemer SR, Talal N, Weisman MH; European Study Group on Classification Criteria for Sjögren's Syndrome. Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis. 2002 Jun;61(6):554-8. Review.</citation>
    <PMID>12006334</PMID>
  </results_reference>
  <results_reference>
    <citation>Schiffman RM, Christianson MD, Jacobsen G, Hirsch JD, Reis BL. Reliability and validity of the Ocular Surface Disease Index. Arch Ophthalmol. 2000 May;118(5):615-21.</citation>
    <PMID>10815152</PMID>
  </results_reference>
  <results_reference>
    <citation>Kojima T, Ishida R, Dogru M, Goto E, Matsumoto Y, Kaido M, Tsubota K. The effect of autologous serum eyedrops in the treatment of severe dry eye disease: a prospective randomized case-control study. Am J Ophthalmol. 2005 Feb;139(2):242-6.</citation>
    <PMID>15733983</PMID>
  </results_reference>
  <results_reference>
    <citation>Tananuvat N, Daniell M, Sullivan LJ, Yi Q, McKelvie P, McCarty DJ, Taylor HR. Controlled study of the use of autologous serum in dry eye patients. Cornea. 2001 Nov;20(8):802-6.</citation>
    <PMID>11685055</PMID>
  </results_reference>
  <results_reference>
    <citation>Leite SC, de Castro RS, Alves M, Cunha DA, Correa ME, da Silveira LA, Vigorito AC, de Souza CA, Rocha EM. Risk factors and characteristics of ocular complications, and efficacy of autologous serum tears after haematopoietic progenitor cell transplantation. Bone Marrow Transplant. 2006 Aug;38(3):223-7. Epub 2006 Jun 19.</citation>
    <PMID>16785864</PMID>
  </results_reference>
  <results_reference>
    <citation>Welder JD, Bakhtiari P, Djalilian AR. Limbitis secondary to autologous serum eye drops in a patient with atopic keratoconjunctivitis. Case Rep Ophthalmol Med. 2011;2011:576521. doi: 10.1155/2011/576521. Epub 2011 Dec 21.</citation>
    <PMID>22606467</PMID>
  </results_reference>
  <results_reference>
    <citation>McDonnell PJ, Schanzlin DJ, Rao NA. Immunoglobulin deposition in the cornea after application of autologous serum. Arch Ophthalmol. 1988 Oct;106(10):1423-5. Review.</citation>
    <PMID>3052385</PMID>
  </results_reference>
  <results_reference>
    <citation>Poon AC, Geerling G, Dart JK, Fraenkel GE, Daniels JT. Autologous serum eyedrops for dry eyes and epithelial defects: clinical and in vitro toxicity studies. Br J Ophthalmol. 2001 Oct;85(10):1188-97.</citation>
    <PMID>11567963</PMID>
  </results_reference>
  <results_reference>
    <citation>Geerling G, Maclennan S, Hartwig D. Autologous serum eye drops for ocular surface disorders. Br J Ophthalmol. 2004 Nov;88(11):1467-74. Review.</citation>
    <PMID>15489495</PMID>
  </results_reference>
  <results_reference>
    <citation>Cho YK, Huang W, Kim GY, Lim BS. Comparison of autologous serum eye drops with different diluents. Curr Eye Res. 2013 Jan;38(1):9-17. doi: 10.3109/02713683.2012.720340. Epub 2012 Aug 28.</citation>
    <PMID>22928476</PMID>
  </results_reference>
  <results_reference>
    <citation>Fischer KR, Opitz A, Böeck M, Geerling G. Stability of serum eye drops after storage of 6 months. Cornea. 2012 Nov;31(11):1313-8. doi: 10.1097/ICO.0b013e3182542085.</citation>
    <PMID>22955119</PMID>
  </results_reference>
  <results_reference>
    <citation>Jeng BH, Dupps WJ Jr. Autologous serum 50% eyedrops in the treatment of persistent corneal epithelial defects. Cornea. 2009 Dec;28(10):1104-8. doi: 10.1097/ICO.0b013e3181a2a7f6.</citation>
    <PMID>19730088</PMID>
  </results_reference>
  <results_reference>
    <citation>Kojima T, Higuchi A, Goto E, Matsumoto Y, Dogru M, Tsubota K. Autologous serum eye drops for the treatment of dry eye diseases. Cornea. 2008 Sep;27 Suppl 1:S25-30. doi: 10.1097/ICO.0b013e31817f3a0e.</citation>
    <PMID>18813071</PMID>
  </results_reference>
  <results_reference>
    <citation>Noble BA, Loh RS, MacLennan S, Pesudovs K, Reynolds A, Bridges LR, Burr J, Stewart O, Quereshi S. Comparison of autologous serum eye drops with conventional therapy in a randomised controlled crossover trial for ocular surface disease. Br J Ophthalmol. 2004 May;88(5):647-52.</citation>
    <PMID>15090417</PMID>
  </results_reference>
  <results_reference>
    <citation>Urzua CA, Vasquez DH, Huidobro A, Hernandez H, Alfaro J. Randomized double-blind clinical trial of autologous serum versus artificial tears in dry eye syndrome. Curr Eye Res. 2012 Aug;37(8):684-8. doi: 10.3109/02713683.2012.674609. Epub 2012 Jun 6.</citation>
    <PMID>22670856</PMID>
  </results_reference>
  <results_reference>
    <citation>Ding C, Walcott B, Keyser KT. Sympathetic neural control of the mouse lacrimal gland. Invest Ophthalmol Vis Sci. 2003 Apr;44(4):1513-20.</citation>
    <PMID>12657587</PMID>
  </results_reference>
  <results_reference>
    <citation>Stevenson W, Chauhan SK, Dana R. Dry eye disease: an immune-mediated ocular surface disorder. Arch Ophthalmol. 2012 Jan;130(1):90-100. doi: 10.1001/archophthalmol.2011.364. Review.</citation>
    <PMID>22232476</PMID>
  </results_reference>
  <results_reference>
    <citation>Sall K, Stevenson OD, Mundorf TK, Reis BL. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study Group. Ophthalmology. 2000 Apr;107(4):631-9. Erratum in: Ophthalmology 2000 Jul;107(7):1220.</citation>
    <PMID>10768324</PMID>
  </results_reference>
  <results_reference>
    <citation>Kunert KS, Tisdale AS, Gipson IK. Goblet cell numbers and epithelial proliferation in the conjunctiva of patients with dry eye syndrome treated with cyclosporine. Arch Ophthalmol. 2002 Mar;120(3):330-7. Erratum in: Arch Ophthalmol 2002 Aug;120(8):1099.</citation>
    <PMID>11879137</PMID>
  </results_reference>
  <results_reference>
    <citation>Kim EC, Choi JS, Joo CK. A comparison of vitamin a and cyclosporine a 0.05% eye drops for treatment of dry eye syndrome. Am J Ophthalmol. 2009 Feb;147(2):206-213.e3. doi: 10.1016/j.ajo.2008.08.015. Epub 2008 Oct 9.</citation>
    <PMID>18848318</PMID>
  </results_reference>
  <results_reference>
    <citation>Demiryay E, Yaylali V, Cetin EN, Yildirim C. Effects of topical cyclosporine a plus artificial tears versus artificial tears treatment on conjunctival goblet cell density in dysfunctional tear syndrome. Eye Contact Lens. 2011 Sep;37(5):312-5. doi: 10.1097/ICL.0b013e31822563be.</citation>
    <PMID>21792057</PMID>
  </results_reference>
  <results_reference>
    <citation>Stonecipher K, Perry HD, Gross RH, Kerney DL. The impact of topical cyclosporine A emulsion 0.05% on the outcomes of patients with keratoconjunctivitis sicca. Curr Med Res Opin. 2005 Jul;21(7):1057-63.</citation>
    <PMID>16004673</PMID>
  </results_reference>
  <results_reference>
    <citation>Barber LD, Pflugfelder SC, Tauber J, Foulks GN. Phase III safety evaluation of cyclosporine 0.1% ophthalmic emulsion administered twice daily to dry eye disease patients for up to 3 years. Ophthalmology. 2005 Oct;112(10):1790-4.</citation>
    <PMID>16102833</PMID>
  </results_reference>
  <results_reference>
    <citation>Behrens A, Doyle JJ, Stern L, Chuck RS, McDonnell PJ, Azar DT, Dua HS, Hom M, Karpecki PM, Laibson PR, Lemp MA, Meisler DM, Del Castillo JM, O'Brien TP, Pflugfelder SC, Rolando M, Schein OD, Seitz B, Tseng SC, van Setten G, Wilson SE, Yiu SC; Dysfunctional tear syndrome study group. Dysfunctional tear syndrome: a Delphi approach to treatment recommendations. Cornea. 2006 Sep;25(8):900-7.</citation>
    <PMID>17102664</PMID>
  </results_reference>
  <results_reference>
    <citation>Toshida H, Nguyen DH, Beuerman RW, Murakami A. Neurologic evaluation of acute lacrimomimetic effect of cyclosporine in an experimental rabbit dry eye model. Invest Ophthalmol Vis Sci. 2009 Jun;50(6):2736-41. doi: 10.1167/iovs.08-1880. Epub 2009 Feb 14.</citation>
    <PMID>19218606</PMID>
  </results_reference>
  <results_reference>
    <citation>Mah F, Milner M, Yiu S, Donnenfeld E, Conway TM, Hollander DA. PERSIST: Physician's Evaluation of Restasis(®) Satisfaction in Second Trial of topical cyclosporine ophthalmic emulsion 0.05% for dry eye: a retrospective review. Clin Ophthalmol. 2012;6:1971-6. doi: 10.2147/OPTH.S30261. Epub 2012 Nov 28.</citation>
    <PMID>23226002</PMID>
  </results_reference>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>February 20, 2018</study_first_submitted>
  <study_first_submitted_qc>September 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 12, 2018</study_first_posted>
  <last_update_submitted>September 9, 2018</last_update_submitted>
  <last_update_submitted_qc>September 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Usak State Hospital</investigator_affiliation>
    <investigator_full_name>Seref istek</investigator_full_name>
    <investigator_title>Uşak University Training and Research Hospital, Department of Ophthalmology, Eye Clinic, Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>dry eye</keyword>
  <keyword>autologous serum</keyword>
  <keyword>cyclosporine ophthalmic emulsion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratoconjunctivitis Sicca</mesh_term>
    <mesh_term>Dry Eye Syndromes</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Ophthalmic Solutions</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>study data can be shared</ipd_description>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>study is finished</ipd_time_frame>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 11, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/84/NCT03666884/SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>May 11, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/84/NCT03666884/Prot_001.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>October 11, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/84/NCT03666884/ICF_002.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

